Insulin-like Growth Factor 1 in Hearing Loss Patophysiology


  • Anggita Dwi Paramitha
  • Tri Umiana Soleha
  • Putu Ristyaning Ayu



Insulin-like Growth Factor 1, patophysiology, sensorineural hearing loss


Sensorineural hearing loss (SNHL) is considered a disease that cannot be treated due to irreversible nerve damage. SNHL occurs due to damage to the inner ear/cochlea namely hair cells and supporting cells (HCs and SCs). Hair cells that carry the sound into neurochemical damage are triggered by ROS. There are several factors that affect hearing loss. Insulin-like growth factor-I (IGF-I) belongs to the family of insulin polypeptides, which play a central role in embryonic development and adult nervous system homeostasis by endocrine, autocrine, and paracrine mechanisms. IGF-I is the basis for regulation of cochlear development, growth, and differentiation, and its mutation is related to hearing loss. Low IGF-I levels have been shown to correlate with various human syndromes that show a hearing loss.  


Lassale, C., Batty, G. D., Ste, A., & Zaninotto, P. Insulin-like Growth Factor 1 in relation to future hearing impairment : findings from the English Longitudinal Study of Ageing. Scientific Reports. 2017; 7(4212): 1–9.

Wong, A. C. Y., & Ryan, A. F. Mechanisms of sensorineural cell damage, death and survival in the cochlea. Frontiers in Aging Neuroscience. 2015; 7(58): 1–15.

Murillo-Cuesta, S., Rosa, L. R. la, Cediel, R., Lassaletta, L., & Varela-Nieto, I. The role of insulin-like growth factor-I in the physiopathology of hearing. Frontiers in Molecular Neuroscience. 2011; 4(11): 1–17.

Yamamoto, N., Nakagawa, T., & Ito, J. Application of insulin-like growth factor-1 in the treatment of inner ear disorders. Frontiers in Pharmacology. 2014; 5(208): 1–9.

Varela-Nieto, I., Murillo-Cuesta, S., Rosa, L. R. la, Lassaletta, L., & Contreras, J. IGF-I Deficiency and Hearing Loss: Molecular Clues and Clinical Implications. Pediatric Endocrinology Reviews (PER). 2013; 10(4): 460–472.

Riquelme, R., Cediel, R., Contreras, J., Rosa, L. R. la, Murillo-Cuesta, S., Hernandez-Sanchez, C., Varela-Nieto, I. A comparative study of age-related hearing loss in wild type and insulin-like growth factor I deficient mice. Frontiers in Neuroanatomy. 2010; 4(27): 1–13.

Iwai K, Nakagawa T, Endo T, Matsuoka Y, Kita T, Kim TS, Tabata Y, Ito J. Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel. Laryngoscope 2006; 116:529-533

Attias J, Zarchi O, Nageris BI, Laron Z. Cochlear hearing loss in patients with Laron syndrome. Eur Arch Otorhinolaryngol 2012;269:461-466

Magarinos M, Contreras J, Aburto MR, Varela-Nieto I. Early development of the vertebrate inner ear. Anat Rec (Hoboken) 2012;295: 1775-90

Nakagawa, T., Sakamoto, T., Hiraumi, H., Kikkawa, Y. S., Yamamoto, N., Hamaguchi, K., Ito, J. 2010. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid- resistant sudden sensorineural hearing loss : a prospective clinical trial. BMC Medicine. 8(76): 1–7.

Nakagawa, T., Ogino-Nishimura, E., Hiraumi, H., Sakamoto, T., Yamamoto, N., and Ito, J. Audiometric outcomes of topical IGF1 treatment for sud- den deafness refractory to systemic steroids. Otol. Neurotol. 2012; 33: 941–946.



How to Cite

Anggita Dwi Paramitha, Tri Umiana Soleha, & Putu Ristyaning Ayu. (2019). Insulin-like Growth Factor 1 in Hearing Loss Patophysiology. Medical Profession Journal of Lampung, 9(2), 275-281.




Most read articles by the same author(s)

1 2 3 4 5 > >>